CTOs on the Move

Synthekine

www.synthekine.com

 
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Synthekine raised $82M on 09/17/2020
Synthekine raised $107.5M on 06/10/2021

Similar Companies

Comprehensive Blood and Cancer Center

CBCC has treated over 75,000 patients since we first opened. We have continually expanded and have earned the recognition as the largest free standing, privately held cancer center in the nation. While our motivation has always been to offer the finest care available, our story starts in a small office in 1984. Dr. Ravi Patel opened a 1200 square foot cancer clinic as a way to bring his vision of providing cancer patients with specialized medical and emotional care to Bakersfield. In the years since, CBCC has changed in many ways, but the purpose has always remained the same—we believe you shouldn`t have to travel the state for state-of-the-art cancer care.

Colorado BioScience Association

Colorado BioScience Association is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Icosavax

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.

Accelerated Technologies Partners

Accelerated Technologies Partners is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Good Therapeutics

Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.